Clinical Immunotherapeutics

, Volume 1, Issue 6, pp 449–459 | Cite as

Role of Colony-Stimulating Factors During High Dosage Chemotherapy

  • Samuel Ariad
  • David Geffen
Review Article Disease Treatment Review

Summary

The advent of recombinant colony-stimulating factors (CSFs) for clinical use in neutropenic states has focused attention on their potential benefit in combination with high dosage cancer chemotherapy (HDCT). HDCT has been used with substantial success for salvage and consolidation therapy and, more recently, for initial therapy. However, its use has been associated with profound myelosuppression. Rescue techniques such as bone marrow stem cell transplantation and/or peripheral blood progenitor cell support may well shorten myelosuppression but do not eliminate it completely.

Granulocyte-macrophage CSF and granulocyte CSF have been the most extensively investigated CSFs in clinical trials. Following marrow transfusion, administration of CSFs may decrease the duration of neutropenia, reduce the need for antibiotics, and shorten hospitalisation. Although CSFs were initially used only to enhance bone marrow recovery after marrow infusion, other new applications were subsequently discovered. CSFs may be used to mobilise peripheral blood progenitor cells for bone marrow support, or even for marrow stem cell substitution. In patients with graft failure, GSFs have been used in an attempt to rescue the failing marrow.

As experience with these agents has accumulated, the optimal use of each single CSF, such as dosage, schedule, specific treatment regimen and costs, has become better defined. As a result, protocols for HDGT incorporating the use of CSFs are becoming routine. Such use of CSFs has made HDCT a procedure that is better tolerated, more convenient to use on a large scale, and probably cheaper.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Frie III E, Canellos GP. Dose: a critical factor in cancer chemotherapy. Am J Med 1980; 69: 585–94CrossRefGoogle Scholar
  2. 2.
    Fefer A, Cheever MA, Greenberg PD. Identical-twin (syngeneic) marrow transplantation for hematologic cancers. J Natl Cancer Inst 1986; 76: 1269–73PubMedGoogle Scholar
  3. 3.
    Appelbaum FR, Thomas ED. Review of the use of marrow transplantation in the treatment of non-Hodgkins lymphoma. J Clin Oncol 1983; 1: 440–7PubMedGoogle Scholar
  4. 4.
    Metcalf D. Haemopoietic growth factors. Med J Aust 1988; 148: 516–19PubMedGoogle Scholar
  5. 5.
    Demetri GD, Antman KH. Granulocyte-macrophage colony-stimulating factor (GM-CSF): preclinical and clinical investigations. Semin Oncol 1992; 362–85Google Scholar
  6. 6.
    Demetri GD, Griffin JD. Granulocyte colony-stimulating factor and its receptor. Blood 1991; 78: 2791–808PubMedGoogle Scholar
  7. 7.
    Warren MK, Ralph P. Macrophage growth factor CSF-1 stimulates human monocyte production of interferon, tumor necrosis factor, and colony-stimulating activity. J Immunol 1986; 137: 2281–5PubMedGoogle Scholar
  8. 8.
    Hume DA, Pavli P, Donahue RE, et al. The effect of human recombinant macrophage colony-stimulating factor (CSF-1) on the murine mononuclear phagocytic system in vivo. J Immunol 1988; 141: 3405–9PubMedGoogle Scholar
  9. 9.
    Bagby GC. Interleukin-1 and hematopoiesis. Blood Rev 1989; 3: 152–61PubMedCrossRefGoogle Scholar
  10. 10.
    Dinarello CA. Interleukin-1 and interleukin-1 antagonism. Blood 77: 1627–52Google Scholar
  11. 11.
    Lopez AF, To LB, Yang YC, et al. Stimulation of proliferation and function of human cells by primate interleukin-3. Proc Natl Acad Sci USA 1987; 84: 2761–5PubMedCrossRefGoogle Scholar
  12. 12.
    McNiece I, Stewart F, Deacon D, et al. Detection of human CSF with a high proliferative potential. Blood 1989; 74: 609–12PubMedGoogle Scholar
  13. 13.
    Zsebo K, Wypych J, McNiece I, et al. Identification, purification and biological characterization of hematopoietic stem cell factor from buffalo rat liver conditioned medium. Cell 1990; 63: 195–201PubMedCrossRefGoogle Scholar
  14. 14.
    Migliaccio G, Migliaccio AR, Druzin ML, et al. Long-term generation of colony-forming cells in liquid culture of CD34+ cord blood cells in the presence of recombinant human stem cell factor. Blood 1992; 79: 2620–7PubMedGoogle Scholar
  15. 15.
    Brandt SJ, Peters WP, Atwater SK, et al. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on hematopoietic reconstitution after high-dose chemotherapy and autologous bone marrow transplantation. N Engl J Med 1988; 318: 869–76PubMedCrossRefGoogle Scholar
  16. 16.
    Blazar BR, Kersy JH, McGlave PB, et al. In vivo administration of recombinant human granulocyte-macrophage factor in acute lymphoblastic leukemia patients receiving purged autografts. Blood 1989; 73: 849–57PubMedGoogle Scholar
  17. 17.
    Nemunatis J, Singer JW, Buckner CD, et al. Use of recombinant human granulocyte-macrophage colony-stimulating factor in autologous marrow transplantation for lymphoid malignancies. Blood 1988; 72: 834–6Google Scholar
  18. 18.
    Gianni AM, Bregni M, Stern AC, et al. Granulocyte-macrophage colony-stimulating factor to harvest circulating haemopoeitic stem cells for autotransplantation. Lancet 1989; 2: 580–5PubMedCrossRefGoogle Scholar
  19. 19.
    Devereaux S, Linch DC, Gribben JG, et al. GM-CSF accelerates neutrophil recovery after autologous transplantation for Hodgkin’s disease. Bone Marrow Transplant 1989; 4: 49–54PubMedGoogle Scholar
  20. 20.
    Powles R, Smith C, Milan S, et al. Human recombinant GM-CSF in allogeneic bone marrow transplantation. A placebo-controlled trial. Lancet 1990; 336: 1417–20PubMedCrossRefGoogle Scholar
  21. 21.
    Nemunaitis J, Rabinowe SN, Singer JW, et al. Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer. N Engl J Med 1991; 324: 1773–8PubMedCrossRefGoogle Scholar
  22. 22.
    Link H, Boogarets MA, Carella AM, et al. A controlled trial of recombinant human granulocyte-macrophage colony-stimulating factor after total body irradiation, high-dose chemotherapy, and autologous bone marrow transplantation for acute lymphoblastic leukemia or malignant lymphoma. Blood 1992; 80: 2188–95PubMedGoogle Scholar
  23. 23.
    Gorin NC, Coiffier B, Hayat M, et al. Recombinant human granulocyte-macrophage stimulating factor after high-dose chemotherapy and autologous bone-marrow transplantation with unpurged and purged marrow in non-Hodgkin’s lymphoma: a double-blind placebo-controlled trial. Blood 1992; 80: 1149–57PubMedGoogle Scholar
  24. 24.
    Gulati SC, Bennett CL. Granulocyte-macrophage colony-stimulating factor (GM-CSF) as adjunct therapy in relapsed Hodgkin disease. Ann Intern Med 1992; 116: 177–82PubMedGoogle Scholar
  25. 25.
    Advani R, Chao NJ, Homing SJ, et al. Granulocyte-macrophage colony-stimulating factor (GM-CSF) as an adjunct to autologous haemopoietic stem cell transplantation for lymphoma. Ann Intern Med 1992; 116: 183–9PubMedGoogle Scholar
  26. 26.
    Peters WP, Kurtzberg J, Kirkpatrick G, et al. GM-CSF primed peripheral blood progenitor cells (PBPC) coupled with autologous bone marrow transplantation (ABMT) will eliminate absolute leukopenia following high-dose chemotherapy (HDC). Blood 1989; 74: 50Google Scholar
  27. 27.
    Sheridan WP, Morstyn G, Wolf M, et al. Granulocyte colony-stimulating factor and neutrophil recovery after high-dose chemotherapy and autologous bone marrow transplantation. Lancet 1989; 2: 891–5PubMedCrossRefGoogle Scholar
  28. 28.
    Masaoka T, Takaku F, Kato S, et al. Recombinant human granulocyte colony-stimulating factor in allogeneic transplantation. Exp Hematol 1989; 17: 1047–50PubMedGoogle Scholar
  29. 29.
    Taylor KM, Jagannath S, Spitzer G, et al. Recombinant human granulocyte colony-stimulating factor hastens recovery after high-dose chemotherapy and autologous bone marrow transplantation in Hodgkin’s disease. J Clin Oncol 1989; 7: 1791PubMedGoogle Scholar
  30. 30.
    Masaoka T, Moriyama Y, Kata S, et al. A randomized, placebo-controlled study of KRN8601 (G-CSF) in patients with bone marrow transplantation. Jpn J Med 1990; 3: 233–9Google Scholar
  31. 31.
    Wilson WH, Bryant G, Jain V, et al. Phase I study of infusional interleukin-1 alpha with ifosfomide, carboplatin and etoposide and autologous bone marrow transplant. Proc Annu Meet Am Soc Clin Oncol 1992; 11: A1146Google Scholar
  32. 32.
    Fibbe WE, Raemaekers J, Verdonck LF, et al. Human recombinant interleukin-3 after autologous bone marrow transplantation for malignant lymphoma. Ann Oncol 1992; 3 Suppl. 1: 163Google Scholar
  33. 33.
    Peters WP, Ross M, Vredenburgh JJ, et al. Comparative effects of GM-CSF and G-CSF on priming for collection of peripheral blood progenitors for use after high-dose chemotherapy. Blood 1993; 81: 1710Google Scholar
  34. 34.
    De Witte T, Gratwohl A, Van Der Lely N, et al. A multicentre double blind randomized trial of recombinant human granulocyte-macrophage colony-stimulating factor in recipients of allogeneic T-cell depleted bone marrow. Blood 1990; 76 Suppl. 1: 139aGoogle Scholar
  35. 35.
    Masaoka T, Motoyoshi K, Takaku F, et al. Administration of human urinary colony stimulating factor after bone marrow transplantation. Bone Marrow Transplant 1988; 3: 121–7PubMedGoogle Scholar
  36. 36.
    Hollingshead LM, Goa KL. Recombinant granulocyte colony-stimulating factor (rG-CSF): a review of its pharmacological properties and prospective role in neutropenic conditions. Drugs 1991; 42: 300–30PubMedCrossRefGoogle Scholar
  37. 37.
    Cline MJ, Golde DW. Mobilization of hematopoietic stem-cells (CFUc) into the peripheral blood of man by endotoxin. Exp Hematol 1977; 5: 186–90PubMedGoogle Scholar
  38. 38.
    Korbling M, Fliedner TM, Calco W, et al. Albumin density gradient purification of canine haemopoietic blood stem-cells: long term allogeneic engraftment without GVH reaction. Exp Hematol 1979; 7: 277–80PubMedGoogle Scholar
  39. 39.
    Richmann CM, Weiner RS, Yankee RA. Increase in circulating cells following chemotherapy in man. Blood 1976; 47: 1031–9Google Scholar
  40. 40.
    Socinski MA, Cannistra SA, Elias A, et al. Granulocyte-macrophage colony-stimulating factor expands the circulating haemopoietic progenitor cell compartment in man. Lancet 1988; 1: 1194–8PubMedCrossRefGoogle Scholar
  41. 41.
    Kessinger A, Armitage JO. The evolving role of autologous peripheral stem cell transplantation following high-dose therapy for malignancies. Blood 1991; 77: 211–13PubMedGoogle Scholar
  42. 42.
    Sheridan WP, Begley CG, Juttner CA, et al. Effect of peripheral blood progenitor cells mobilised by filgrastin (G-CSF) on platelet recovery after high-dose chemotherapy. Lancet 1992; 339: 640–4PubMedCrossRefGoogle Scholar
  43. 43.
    Elias AD, Ayash L, Anderson KC, et al. Mobilization of peripheral blood progenitor cells by chemotherapy and granulocyte-macrophage colony-stimulating factor for hematologic support after high-dose intensification for breast cancer. Blood 1992; 79: 3036–44PubMedGoogle Scholar
  44. 44.
    Chao NJ, Schriber JR, Grimes K, et al. Granulocyte colony-stimulating factor mobilized peripheral blood progenitor cells accelerate granulocyte and platelet recovery after high-dose chemotherapy. Blood 1993; 81: 2031–5PubMedGoogle Scholar
  45. 45.
    Bensinger W, Singer J, Appelbaum F, et al. Autologous transplantation with peripheral blood mononuclear cells collected after administration of recombinant granulocyte stimulating factor. Blood 1993; 81: 3158–63PubMedGoogle Scholar
  46. 46.
    Bishop RB, Anderson JR, Jackson JD, et al. High-dose therapy and peripheral blood progenitor cell transplantation: effects of recombinant human granulocyte-macrophage colony-stimulating factor on the autograft. Blood 1994; 83: 610–6PubMedGoogle Scholar
  47. 47.
    Pettengell R, Testa NG, Swindell R, et al. Transplantation potential of hematopoietic cells released into the circulation during routine chemotherapy for non-Hodgkin’s lymphoma. Blood 1993; 82: 2239–48PubMedGoogle Scholar
  48. 48.
    Lemoli RM, Tafuri A, Strife A, et al. Proliferation of human hematopoietic progenitors in long-term bone marrow cultures in gas-permeable plastic bags is enhanced by colony-stimulating factors. Exp Hematol 1992; 20: 569–75PubMedGoogle Scholar
  49. 49.
    Nemunaitis J, Singer JW, Buckner CD, et al. Use of recombinant human granulocyte-macrophage colony-stimulating factor in graft failure after bone marrow transplantation. Blood 1990; 76: 245–53PubMedGoogle Scholar
  50. 50.
    Brandwein JM, Nayar R, Baker MA, et al. GM-CSF therapy for delayed engraftment after autologous bone marrow transplantation. Exp Hematol 1991; 19: 191–5PubMedGoogle Scholar
  51. 51.
    Crump M, Couture F, Kovacs M, et al. Interleukin-3 followed by GM-CSF for delayed engraftment after autologous bone marrow transplantation. Exp Hematol 1993; 21: 405–10PubMedGoogle Scholar
  52. 52.
    Donahue RE, Seehra J, Metzger M, et al. Human IL-3 and GM-CSF act synergistically in stimulating hematopoiesis in primates. Science 1988; 241: 1820–3PubMedCrossRefGoogle Scholar
  53. 53.
    Wheeler C, Guinan E, Sieff C, et al. Interleukin 3 before marrow harvest and GM-CSF post autotransplant in patients with relapsed lymphoma: no enhancement of hematopoietic recovery. Blood 1992; 80 Suppl. 1: 85a; [abstract 330]Google Scholar
  54. 54.
    Masaoka T, Takaku F. Recombinant human granulocyte colony-stimulating factor in allogeneic bone marrow transplantation [abstract]. Proceedings of the 7th Congress of the Asian-Pacific Division of the International Society of Haematology; 1991 Nov 17–21; Hong Kong. 1991: 91Google Scholar
  55. 55.
    Faulds D, Lewis NJW, Milne RJ. Recombinant granulocyte colony-stimulating factor (rG-CSF): pharmacoeconomic considerations in chemotherapy-induced neutropenia. Pharmaco-Economics 1992; 1: 231–49CrossRefGoogle Scholar

Copyright information

© Adis International Limited 1994

Authors and Affiliations

  • Samuel Ariad
    • 1
  • David Geffen
    • 1
  1. 1.Department of Oncology, Soroka Medical Centre, Faculty of Health SciencesBen-Gurion University of the NegevBeer-ShevaIsrael
  2. 2.Oncology InstituteSoroka Medical CentreBeer-ShevaIsrael

Personalised recommendations